Related Experiment Videos

MMR vaccine and idiopathic thrombocytopaenic purpura

Corri Black1, James A Kaye, Hershel Jick

  • 1Department of Public Health, Aberdeen University, Aberdeen, UK. corri.black@abdn.ac.uk

Abstract

Insights

The measles, mumps, and rubella (MMR) vaccine is associated with a higher risk of idiopathic thrombocytopaenic purpura (ITP) in children. However, the overall risk of ITP following MMR vaccination remains low.

Area of Science:

  • Pediatric Immunology
  • Vaccine Safety Research
  • Epidemiology

Background:

  • Idiopathic thrombocytopaenic purpura (ITP) is a bleeding disorder characterized by low platelet counts.
  • The measles, mumps, and rubella (MMR) vaccine is a routine childhood immunization.
  • Investigating potential associations between vaccinations and adverse events is crucial for public health.

Purpose of the Study:

  • To determine the relationship between the MMR vaccine and the incidence of ITP in children.
  • To calculate the relative risk and attributable risk of ITP following MMR vaccination.

Main Methods:

  • A population-based case-control study was conducted using the General Practice Research Database.
  • Children under 6 years old diagnosed with ITP between January 1988 and December 1999 were identified.
  • A specific analysis focused on children aged 13-24 months to assess ITP risk within 6 weeks post-MMR vaccination.

Main Results:

  • Sixty-three children were diagnosed with ITP; 23 were aged 13-24 months.
  • The relative risk of ITP within 6 weeks after MMR vaccination was 6.3 (95% CI 1.3-30.1).
  • The attributable risk of ITP within 6 weeks of MMR vaccination was estimated at 1 in 25,000 vaccinations.

Conclusions:

  • This study confirms an elevated risk of ITP within 6 weeks after MMR vaccination.
  • Despite the increased relative risk, the attributable risk of ITP following MMR vaccination is low.

Related Concept Videos